It’s the 20th year we’ve sought out the most innovative private biotechs, which also means we've entered the second decade we've been checking in on our past honorees.

Alnylam has reached a phase 2 checkpoint of its Regeneron-partnered immunoglobulin A nephropathy treatment as it looks to catch up with Calliditas Therapeutics' FDA-approved med Tarpeyo. 

A research team led by scientists at the University of California, San Francisco has uncovered a gene involved in the regulation of T-cell immunity. Using CRISPR to inactivate the gene helped TCR and CAR T cells become more resilient and sensitive and prolonged survival in mice carrying either liquid or solid tumors.

At the European Society of Cardiology’s annual meeting, AstraZeneca presented data that could boost Farxiga in the competitive heart failure market. It is the first heart failure drug to show it can reduce the risk of death in patients regardless of their ejection fraction status.

Forrester healthcare analysts called the shuttering of Amazon Care "a strategic move" rather than a failure. Amazon still has its sights set on primary care, many healthcare experts say, as it represents the gatekeeper of patient care.

A heart pump from Abbott may give at least five years back to severe heart failure patients, according to clinical trial results presented this week at the 2022 European Society of Cardiology Congress in Spain.

The expansion, which is pending regulatory approval, will bring Cigna's total ACA footprint to 363 counties across 16 states, the insurer said.

After days of swirling speculation, Olympus finally confirmed this week that it has agreed to sell off its scientific solutions business to Bain Capital Private Equity.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.